89723-87-5

Upstream product

• 89723-86-4 4-hydroxymethyl-5-methyl-2-styryloxazole 
• 14371-10-9 (E)-3-phenylpropenal 
• 108-20-3 di-isopropyl ether 
• 102-92-1 Cinnamoyl chloride 
• 89723-84-2 ethyl 2-cinnamoylaminoacetoacetate 
• 89723-85-3 (E)-ethyl 5-methyl-2-styryloxazole-4-carboxylate 

Downstream Products

• 89723-88-6 5-methyl-2-styryl-4-oxazoleacetonitrile 
• 107368-11-6 5-methyl-2-styryl-4-oxazolepropionic acid 
• 89723-89-7 5-methyl-2-styryl-4-oxazoleacetic acid 

Relevant academic research and scientific papers

Novel hexafluoroisopropanol derivatives

The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein R1 to R6, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. The

Indolyl derivatives as liver-X-receptor (LXR) modulators

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as pharmaceutical compositions for the treatment of, for example, diabetes.

Oxazoleacetic acid derivatives

A compound of the formula: STR1 wherein R1 is (A) a group of the formula, STR2 wherein R4 is H, a halogen or trifluoromethyl group, or (B) a group of the formula, STR3 wherein n is 0 or an integer of 1 to 3; R5 is H or an